PE20150163A1 - Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav - Google Patents

Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav

Info

Publication number
PE20150163A1
PE20150163A1 PE2014001722A PE2014001722A PE20150163A1 PE 20150163 A1 PE20150163 A1 PE 20150163A1 PE 2014001722 A PE2014001722 A PE 2014001722A PE 2014001722 A PE2014001722 A PE 2014001722A PE 20150163 A1 PE20150163 A1 PE 20150163A1
Authority
PE
Peru
Prior art keywords
composition
methods
gene transfer
highly efficient
efficient gene
Prior art date
Application number
PE2014001722A
Other languages
English (en)
Spanish (es)
Inventor
Mustafa Yazicioglu
Federico Mingozzi
Xavier Anguela
Katherine High
Original Assignee
Philadelphia Children Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philadelphia Children Hospital filed Critical Philadelphia Children Hospital
Publication of PE20150163A1 publication Critical patent/PE20150163A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2014001722A 2012-04-18 2013-04-18 Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav PE20150163A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261635273P 2012-04-18 2012-04-18
US201361794995P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PE20150163A1 true PE20150163A1 (es) 2015-02-23

Family

ID=49384070

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001722A PE20150163A1 (es) 2012-04-18 2013-04-18 Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav

Country Status (26)

Country Link
US (2) US9909142B2 (OSRAM)
EP (1) EP2839014B1 (OSRAM)
JP (1) JP6342886B2 (OSRAM)
KR (1) KR102063483B1 (OSRAM)
CN (1) CN104487579B (OSRAM)
AU (1) AU2013249202B2 (OSRAM)
BR (2) BR122021020419B1 (OSRAM)
CA (1) CA2870736C (OSRAM)
CO (1) CO7200251A2 (OSRAM)
DK (1) DK2839014T3 (OSRAM)
ES (1) ES2862912T3 (OSRAM)
HU (1) HUE054087T2 (OSRAM)
IL (1) IL235102B (OSRAM)
IN (1) IN2014DN08812A (OSRAM)
MX (1) MX359518B (OSRAM)
MY (1) MY172457A (OSRAM)
NZ (1) NZ701693A (OSRAM)
PE (1) PE20150163A1 (OSRAM)
PH (1) PH12014502347B1 (OSRAM)
PL (1) PL2839014T3 (OSRAM)
PT (1) PT2839014T (OSRAM)
RU (1) RU2683497C2 (OSRAM)
SG (1) SG11201406776TA (OSRAM)
SI (1) SI2839014T1 (OSRAM)
WO (1) WO2013158879A1 (OSRAM)
ZA (1) ZA201407582B (OSRAM)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3409296A1 (en) * 2005-04-07 2018-12-05 The Trustees of the University of Pennsylvania Method of increasing the function of an aav vector
ES2714007T3 (es) 2007-04-09 2019-05-24 Univ Florida Composiciones de vectores rAAV que tienen proteínas de la cápside modificadas en tirosina y métodos para su uso
US9725485B2 (en) * 2012-05-15 2017-08-08 University Of Florida Research Foundation, Inc. AAV vectors with high transduction efficiency and uses thereof for gene therapy
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
CN103501787A (zh) 2011-04-29 2014-01-08 西莱克塔生物科技公司 用于产生cd8+调节性t细胞的致耐受性合成纳米载体
BR122021020419B1 (pt) 2012-04-18 2023-01-17 The Children's Hospital Of Philadelphia Vetor de vírus adeno-associado (aav) que compreende uma proteína de capsídeo vp1, composições farmacêuticas compreendendo o mesmo, e seus usos
US10294281B2 (en) 2012-05-15 2019-05-21 University Of Florida Research Foundation, Incorporated High-transduction-efficiency rAAV vectors, compositions, and methods of use
US12358954B2 (en) 2012-05-15 2025-07-15 University Of Florida Research Foundation, Incorporated Capsid-modified rAAV vector compositions and methods therefor
EP3003391B1 (en) * 2013-05-31 2021-09-22 The Regents of The University of California Adeno-associated virus variants and methods of use thereof
IL297919A (en) * 2013-07-22 2023-01-01 Childrens Hospital Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
EP3049527A4 (en) 2013-09-26 2017-08-16 University of Florida Research Foundation, Inc. Synthetic combinatorial aav capsid library for targeted gene therapy
GB201403684D0 (en) * 2014-03-03 2014-04-16 King S College London Vector
WO2015134643A1 (en) * 2014-03-04 2015-09-11 University Of Florida Research Foundation, Inc. Improved raav vectors and methods for transduction of photoreceptors and rpe cells
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
EP3188742A4 (en) 2014-09-07 2018-04-18 Selecta Biosciences, Inc. Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
JP7023108B2 (ja) 2014-10-21 2022-02-21 ユニバーシティ オブ マサチューセッツ 組み換えａａｖバリアントおよびその使用
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
AU2015346162B2 (en) 2014-11-14 2022-02-10 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
ES2878451T3 (es) 2014-11-14 2021-11-18 Voyager Therapeutics Inc Polinucleótidos moduladores
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
US20180030096A1 (en) 2015-02-03 2018-02-01 University Of Florida Research Foundation, Inc. Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
US10648000B2 (en) 2015-02-16 2020-05-12 University Of Florida Research Foundation, Incorporated rAAV vector compositions, methods for targeting vascular endothelial cells and use in treatment of type I diabetes
WO2016134337A1 (en) * 2015-02-19 2016-08-25 University Of Florida Research Foundation, Inc. Site-specific integrating recombinant aav vectors for gene therapy and improved production methods
JP6519080B2 (ja) * 2015-06-22 2019-05-29 ライオン株式会社 繊維製品用抗ウイルス組成物
EP3313991B1 (en) 2015-06-23 2024-07-17 The Children's Hospital of Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
BR112018003665A2 (pt) 2015-09-28 2018-09-25 Univ North Carolina Chapel Hill métodos e composições para vetores virais de evasão de anticorpo
WO2017070476A2 (en) 2015-10-22 2017-04-27 University Of Florida Research Foundation, Inc. Synthetic combinatorial aav3 capsid library
HK1257801A1 (zh) 2015-10-28 2019-11-01 宾夕法尼亚州大学信托人 用於基因治療的腺伴隨病毒載體的鞘內給藥
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
AU2016362477A1 (en) 2015-12-02 2018-06-14 Voyager Therapeutics, Inc. Assays for the detection of AAV neutralizing antibodies
MX2018012663A (es) * 2016-04-16 2019-07-08 Univ Florida Metodos para aumentar la capacidad de actividad biológica del virus adenoasociado recombinante producido mediante el sistema baculovirus.
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CR20180589A (es) 2016-05-13 2019-02-27 4D Molecular Therapeutics Inc Cápsulas variantes de virus adenoasociados y métodos de uso de estas
MX2018014154A (es) 2016-05-18 2019-05-06 Voyager Therapeutics Inc Polinucleotidos moduladores.
SG11201809643UA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
SG10201913002QA (en) * 2016-08-15 2020-03-30 Genzyme Corp Methods for detecting aav
US11298041B2 (en) 2016-08-30 2022-04-12 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
KR20240173209A (ko) * 2016-10-13 2024-12-10 유니버시티 오브 매사추세츠 Aav 캡시드 설계
KR20190104194A (ko) 2017-01-07 2019-09-06 셀렉타 바이오사이언시즈, 인크. 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
US11028131B2 (en) * 2017-01-30 2021-06-08 Nippon Medical School Foundation Mutant of adeno-associated virus (AAV) capsid protein
JP7237843B2 (ja) 2017-02-21 2023-03-13 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 修飾されたａａｖキャプシドタンパク質およびその使用
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
KR20250011715A (ko) 2017-03-11 2025-01-21 셀렉타 바이오사이언시즈, 인크. 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물
US10550405B2 (en) 2017-03-15 2020-02-04 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
EP4303225A3 (en) 2017-03-15 2024-04-10 The University of North Carolina at Chapel Hill Polyploid adeno-associated virus vectors and methods of making and using the same
EP3601367B1 (en) 2017-03-30 2024-10-09 The University of Queensland Chimeric molecules and uses thereof
WO2018204786A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
EP3635108A4 (en) 2017-06-07 2021-03-31 Spark Therapeutics, Inc. ACTIVATION AGENTS INTENDED FOR ENHANCED CELL TRANSFECTION AND / OR RAAV VECTOR PRODUCTION
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
US20200121746A1 (en) 2017-06-30 2020-04-23 The Regents Of The University Of California Adeno-associated virus virions with variant capsids and methods of use thereof
EP3654860A1 (en) 2017-07-17 2020-05-27 Voyager Therapeutics, Inc. Trajectory array guide system
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
WO2019040994A1 (en) 2017-09-01 2019-03-07 The Australian National University IMMUNOREGULATOR MOLECULES AND USES THEREOF
CA3076348A1 (en) 2017-09-20 2019-03-28 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and methods of use thereof
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
KR20200086670A (ko) 2017-10-13 2020-07-17 셀렉타 바이오사이언시즈, 인크. 항바이러스 전달 벡터 IgM 반응을 약화시키기 위한 방법 및 조성물
EP3697908A1 (en) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CA3077426A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US11766489B2 (en) 2017-11-27 2023-09-26 4D Molecular Therapeutics, Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
WO2019126356A1 (en) 2017-12-19 2019-06-27 The University Of North Carolina At Chapel Hill Methods and compositions for delivery of viral vectors across the blood-brain barrier
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
KR20200127170A (ko) 2018-02-01 2020-11-10 호몰로지 메디슨, 인크. Pah 유전자 기능 복원을 위한 아데노-연관 바이러스 조성물 및 이의 사용 방법
CN112041437A (zh) 2018-02-19 2020-12-04 同源药物公司 用于恢复f8基因功能的腺相关病毒组合物和其使用方法
CN112384204B (zh) 2018-02-26 2023-03-14 安托瑞斯公司 致耐受性脂质体及其使用方法
IL276859B1 (en) * 2018-02-27 2025-08-01 Univ Pennsylvania Novel adeno-associated virus (AAV) vectors, AAV vectors with reduced capsid deamidation and uses therefor
EP3765624A4 (en) * 2018-03-16 2022-05-25 Research Institute at Nationwide Children's Hospital Increasing tissue specific gene delivery by capsid modification
MX2020010465A (es) 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
US20210363191A1 (en) 2018-04-03 2021-11-25 Stridebio, Inc. Antibody-evading virus vectors
WO2019195444A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
BR112020020223A2 (pt) 2018-04-05 2021-01-19 Genethon Sorotipo de vírus adeno-associado híbrido recombinante entre aav9 e aavrh74 com tropismo pelo fígado reduzido
US20210363192A1 (en) * 2018-04-27 2021-11-25 Spark Therapeutics, Inc. Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same
CA3098198A1 (en) 2018-04-27 2019-10-31 Decibel Therapeutics, Inc. Myosin 15 promoters and uses thereof
US12319929B2 (en) 2018-05-15 2025-06-03 Voyager Therapeutics, Inc. Compositions and methods for the treatment of Parkinson's disease
WO2019222411A1 (en) * 2018-05-16 2019-11-21 Spark Therapeutics, Inc. Codon-optimized acid αlpha-glucosidase expression cassettes and methods of using same
BR112021000675A2 (pt) 2018-07-16 2021-04-13 Selecta Biosciences, Inc. Métodos e composições de construtos e vetores de mma
AU2019308567A1 (en) 2018-07-16 2021-01-28 Selecta Biosciences, Inc. Methods and compositions of OTC constructs and vectors
AU2019346655B2 (en) 2018-09-28 2025-03-13 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
WO2020082046A2 (en) 2018-10-18 2020-04-23 Intellia Therapeutics, Inc. Compositions and methods for expressing factor ix
US11702673B2 (en) 2018-10-18 2023-07-18 University Of Florida Research Foundation, Incorporated Methods of enhancing biological potency of baculovirus system-produced recombinant adeno-associated virus
WO2020163761A1 (en) 2019-02-08 2020-08-13 Decibel Therapeutics, Inc. Myosin 15 promoters and uses thereof
WO2020163743A1 (en) 2019-02-08 2020-08-13 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
EP3931334A1 (en) 2019-02-25 2022-01-05 Novartis AG Compositions and methods to treat bietti crystalline dystrophy
CN113474461A (zh) 2019-02-25 2021-10-01 诺华股份有限公司 治疗bietti晶体营养不良的组合物和方法
BR112021018776A2 (pt) 2019-03-21 2021-11-30 Stridebio Inc Vetores de vírus adenoassociado recombinante
CN114126666A (zh) 2019-04-28 2022-03-01 西莱克塔生物科技公司 用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法
EP3976802A1 (en) 2019-05-28 2022-04-06 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
RU2751592C2 (ru) 2019-08-22 2021-07-15 Общество С Ограниченной Ответственностью "Анабион" Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе
EP4038194A1 (en) 2019-10-04 2022-08-10 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
US20230392163A1 (en) 2019-10-17 2023-12-07 Ginkgo Bioworks Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
CA3222852A1 (en) 2020-01-03 2021-07-08 Sarepta Therapeutics, Inc. Methods for analyzing aav capsid proteins
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
US20230054144A1 (en) 2020-02-14 2023-02-23 Ultragenyx Pharmaceutical Inc. Gene therapy for treating cdkl5 deficiency disorder
EP4121544A1 (en) 2020-03-19 2023-01-25 Ultragenyx Pharmaceutical Inc. Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
WO2021202532A1 (en) 2020-03-31 2021-10-07 Ultragenyx Pharmaceutical Inc. Gene therapy for treating propionic acidemia
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
MX2023002016A (es) 2020-08-19 2023-06-26 Sarepta Therapeutics Inc Vectores de virus adenoasociados para el tratamiento del sindrome de rett.
KR20230085170A (ko) 2020-10-15 2023-06-13 에프. 호프만-라 로슈 아게 동시 유전자 활성화를 위한 핵산 구조체
EP4229205B1 (en) 2020-10-15 2025-05-14 F. Hoffmann-La Roche AG Nucleic acid constructs for va rna transcription
CA3207247A1 (en) 2021-01-05 2022-07-14 Selecta Biosciences, Inc. Viral vector dosing protocols
TW202304954A (zh) * 2021-04-23 2023-02-01 美商佛羅里達大學研究基金會公司 用於肌肉萎縮症之基因療法的aavrh74載體
WO2023019168A1 (en) 2021-08-11 2023-02-16 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating a muscular dystrophy
MA64631B1 (fr) 2021-08-20 2024-12-31 Joint Stock Company "Biocad" Procédé de production de capside modifié de virus adéno-associé
AR126839A1 (es) 2021-08-20 2023-11-22 Llc «Anabion» Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 9 (aav9), cápside y vector basado en esta
AR126840A1 (es) 2021-08-20 2023-11-22 Llc «Anabion» Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en esta
WO2023044306A1 (en) * 2021-09-14 2023-03-23 California Institute Of Technology Aav capsid variants
WO2023064350A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Viral vector dosing protocols
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
JP2024545594A (ja) 2021-11-14 2024-12-10 カーティザン セラピューティクス，インコーポレーテッド ウイルスベクターでの複数回投薬
CN116554278A (zh) * 2022-01-30 2023-08-08 上海玮美基因科技有限责任公司 变异型腺相关病毒及其在疾病治疗中的应用
TW202342740A (zh) 2022-03-07 2023-11-01 美商奧崔基尼克斯製藥公司 改良的批量aav生產系統和方法
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
CN118974274A (zh) 2022-04-13 2024-11-15 豪夫迈·罗氏有限公司 用于确定aav基因组的方法
CN119654334A (zh) * 2022-05-11 2025-03-18 费城儿童医院 用于靶向深层脑结构的腺相关病毒载体
JP2025517987A (ja) 2022-05-23 2025-06-12 エフ． ホフマン－ラ ロシュ アーゲー Ａａｖ粒子血清型およびａａｖ粒子負荷状態の識別のためのラマンベースの方法
AR129500A1 (es) 2022-06-03 2024-09-04 Hoffmann La Roche Método para producir partículas de aav recombinante
EP4554604A1 (en) 2022-07-14 2025-05-21 F. Hoffmann-La Roche AG Method for producing recombinant aav particles
JP2025526816A (ja) 2022-08-11 2025-08-15 カーティザン セラピューティクス，インコーポレーテッド 免疫グロブリンプロテアーゼおよびその融合体に関する組成物および方法
IL317385A (en) 2022-08-15 2025-02-01 Hoffmann La Roche Preventing or reducing side effects associated with recombinant viral vectors
IL318766A (en) 2022-09-12 2025-04-01 Hoffmann La Roche Method for separating full and empty AAV particles
CN120641755A (zh) 2023-02-07 2025-09-12 豪夫迈·罗氏有限公司 用于检测抗aav颗粒抗体的方法
AU2024239386A1 (en) 2023-03-21 2025-08-14 F. Hoffmann-La Roche Ag Method for the production of recombinant aav particle preparations
WO2024213596A1 (en) 2023-04-13 2024-10-17 F. Hoffmann-La Roche Ag Improved recombinant polyadenylation signal sequences and use thereof
WO2025057182A1 (en) * 2023-09-15 2025-03-20 Indian Institute Of Technology Kanpur Modified aav vectors for enhanced gene therapy in hemophilia b
WO2025082618A1 (en) 2023-10-20 2025-04-24 Fuse Vectors Aps In vitro parvovirus capsid manufacturing
WO2025168663A1 (en) 2024-02-09 2025-08-14 F. Hoffmann-La Roche Ag Method for producing recombinant adeno-associated viral particles

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1202962A (en) 1982-10-19 1986-04-08 David P. Clifford Substituted n-phenyl-n'-benzoyl ureas and their use as insecticides and acaricides
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
IL128780A0 (en) 1996-09-06 2000-01-31 Univ Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
JP4888876B2 (ja) 2003-06-13 2012-02-29 田平 武 アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター
EP3409296A1 (en) * 2005-04-07 2018-12-05 The Trustees of the University of Pennsylvania Method of increasing the function of an aav vector
EP2018421B1 (en) 2006-04-28 2012-12-19 The Trustees of the University of Pennsylvania Scalable production method for aav
AU2011238708B2 (en) * 2010-03-29 2016-02-11 The Trustees Of The University Of Pennsylvania Pharmacologically Induced Transgene Ablation system
US9434928B2 (en) 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
BR122021020419B1 (pt) 2012-04-18 2023-01-17 The Children's Hospital Of Philadelphia Vetor de vírus adeno-associado (aav) que compreende uma proteína de capsídeo vp1, composições farmacêuticas compreendendo o mesmo, e seus usos

Also Published As

Publication number Publication date
AU2013249202A1 (en) 2014-11-06
CA2870736A1 (en) 2013-10-24
PT2839014T (pt) 2021-03-19
KR102063483B1 (ko) 2020-01-08
IL235102B (en) 2019-08-29
IN2014DN08812A (OSRAM) 2015-05-22
KR20150004859A (ko) 2015-01-13
JP2015514427A (ja) 2015-05-21
PL2839014T3 (pl) 2021-08-23
RU2014146159A (ru) 2016-06-10
MY172457A (en) 2019-11-26
CO7200251A2 (es) 2015-02-27
US20150065562A1 (en) 2015-03-05
ZA201407582B (en) 2021-05-26
DK2839014T3 (da) 2021-03-08
CN104487579A (zh) 2015-04-01
US11279950B2 (en) 2022-03-22
MX359518B (es) 2018-10-01
PH12014502347A1 (en) 2014-12-22
HUE054087T2 (hu) 2021-09-28
SG11201406776TA (en) 2015-03-30
SI2839014T1 (sl) 2021-05-31
CN104487579B (zh) 2022-01-18
CA2870736C (en) 2021-11-02
BR112014025985A2 (pt) 2017-07-11
NZ701693A (en) 2017-02-24
BR122021020419B1 (pt) 2023-01-17
EP2839014A1 (en) 2015-02-25
JP6342886B2 (ja) 2018-06-13
ES2862912T3 (es) 2021-10-08
IL235102A0 (en) 2014-12-31
US9909142B2 (en) 2018-03-06
MX2014012680A (es) 2015-05-11
EP2839014A4 (en) 2015-12-30
EP2839014B1 (en) 2020-12-16
HK1207663A1 (en) 2016-02-05
RU2683497C2 (ru) 2019-03-28
PH12014502347B1 (en) 2014-12-22
AU2013249202B2 (en) 2018-08-09
WO2013158879A1 (en) 2013-10-24
US20180245098A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
PE20150163A1 (es) Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav
EA201591992A1 (ru) Эффективная доставка больших генов посредством двойных aav векторов
MX2018007237A (es) Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus.
PL3740222T3 (pl) Zmodyfikowane białko kapsydu raav do terapii genowej
CL2019000392A1 (es) Métodos para detectar aav.
EP3368054A4 (en) REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
EP3387137A4 (en) TARGET PEPTIDES FOR LEADING ADENO ASSOCIATED VIRUSES (AAVS)
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
BR112017007737A2 (pt) variantes de aav recombinantes e usos das mesmas
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
MX388146B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
MX377804B (es) Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc).
EP3795581A3 (en) New avv capsid proteins for nucleic acid transfer
WO2014145599A3 (en) Recombinant virus and preparations thereof
MX384795B (es) Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso.
EA201990558A3 (ru) Доставка нацеленных на экзон 2 полинуклеотидных конструкций u7snrna при помощи рекомбинантного аденоассоциированного вируса
EP2678433A4 (en) ADMINISTRATION OF PROTEINS USING AVV (ADENO ASSOCIATED VIRUS) VECTORS
CL2014003464A1 (es) Método para mejorar la integridad deteriorada de la unión neuromuscular que comprende la administración de una composición que comprende un vector viral adeno-asociado recombinante (raav) que comprende una molécula de ácido nucleico que codifica la alfa-glucosidasa ácida (gaa).
CA2872308A1 (en) Novel ha binding agents
MX2016002166A (es) Anticuerpos.
EA201890543A1 (ru) Способы и материалы для генной терапии galgt2
MX383506B (es) Parvovirus porcino.
MX378905B (es) Pestivirus.
CR20170020A (es) Variantes de proteínas de unión al factor h y métodos de uso de estas
MX2019008105A (es) Virus.

Legal Events

Date Code Title Description
FG Grant, registration